GTOnco™ Mixed Lymphocyte Tumor Reactivity Assay
It is vital to determine the immune reactivity of lymphocytes and tumor cells from the same individual to support the gene therapy-based I-O drugs development. Creative Biolabs now presents one-stop mixed lymphocyte tumor cell (MLTuC), also called the mixed lymphocyte tumor reactivity (MLTR) assay, to evaluate the efficiency of I-O products. MLTR assay is a method to assess the immunological reactivity between lymphocytes and tumor cells, such as the induction of primary immune responses to tumor-associated cell-surface antigens. In addition, the assay can be used to generate T-lymphocytes that are cytotoxic to specific tumor cell types. At GTOnco™, we are committed to offering the MLTR assay for our clients to advance their I-O drugs development process.
Figure 1. Simple diagram of MLTR assay at GTOnco™.
Generally, the MLTR assay is performed by the co-culture of targeted tumor cells with lymphocyte populations, including engineered T-cells or primary T cells derived from PBMC. GTOnco™ provides multiple technologies to assess the T cell viability, activation, proliferation, and cytotoxicity after incubated with tumor cells. Additionally, in order to generate T-lymphocytes with enhanced anti-tumor activity, we conduct the MLTR assay via the addition of dendritic cells to present tumor antigens of interest to T-lymphocytes in culture. All our experiments are performed by well-trained and experienced technicians to guarantee quality and reliability.
Features of Our MLTR Assay at GTOnco™ Platform
- Skillful technologies and advanced platforms
- Customized assay design to support per clients' project
- Multiple endpoints are available to clearly understand the I-O profile, including surface markers, cytokines release, T cell activation and proliferation, etc.
Leveraging our extensive experience and advanced platforms, Creative Biolabs is dedicated to providing one-stop MLTR assay service for our clients to rapidly identify the gene therapy-based I-O agents that modulate antigen presenting cell-mediated lymphocyte response and assess the immunological reactivity between lymphocytes and tumor cells. Please contact us and let us know your requirements and we will get back to you as soon as possible.
Reference
- Uchida, A.; et al. (1988). Autologous mixed lymphocyte-tumor reaction and autologous mixed lymphocyte reaction. II. Generation of specific and non-specific killer T cells capable of lysing autologous tumor. International Journal of Cancer. 41(5), pp.651-656.
